Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in Her2-expressing Muscle-invasive Bladder Cancer: A Phase II, Open-Label, Randomized Clinical Trial

This study aims to evaluate the efficacy of disitamab vedotin combined with toripalimab as a bladder-preserving treatment combination in patients with HER2 positive locally advanced MIBC, including one year bladder-intact DFS (BI-DFS) and safety.

NCT Number	NCT07151560
Lead Sponsor	Renmin Hospital of Wuhan University
Conditions	Urology
Enrollment	60 participants
Start Date	2025-08-30
Primary Completion	2027-08-30 (estimated)
Study Completion	2030-08-30 (estimated)
Updated on ClinicalTrials.gov	2025-09-03